ReviewFunctional & integrative genomics2025
LncRNAs in hypoxic microenvironment; insight in their impact in cancer biology.
Review in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The lncRNA-DNA Methylation Axis in Hepatocellular Carcinoma: Mechanisms, Epigenetic Plasticity, and Biological Implications.Biology · 2026Review
- The Oncogenic Role of Long Non-Coding RNABiology · 2026Review
- Integrative Pan-Cancer Characterization of lncRNA UPK1A-AS1 and Its Role in Hypoxia-Associated Sorafenib Resistance in Hepatocellular Carcinoma.Analytical cellular pathology (Amsterdam) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hypoxia may facilitate metastasis and tumor advancement in solid tumors. Intratumoral hypoxia may facilitate tumor aggressiveness by stabilizing hypoxia-inducible factor-1α (HIF-1α). Various transcriptional and epigenetic pathways modulate hypoxia-stimulated gene expression and tumor progression. Noncoding RNAs longer than 200 nt are long noncoding RNAs (lncRNAs). Current lncRNA profiling in several human tumor types revealed that lncRNA expression and deregulation vary by tumor type and may undergo transcriptional, genomic, and epigenetic modifications. LncRNAs controlled by hypoxia have emerged as a prominent focus in hypoxia-regulated biology due to their ability to influence multiple biological procedures associated with tumorigenesis. Hypoxia-regulated lncRNAs may influence tumor development, growth, anti-apoptosis, migration, invasion, angiogenesis, and tumor metabolism. In this light, hypoxia-inducible lncRNAs could interact with protein/protein complex and chromatin/epigenetic factors and another mechanism, thus favoring tumorigenesis. Conversely, lncRNAs may control hypoxia signaling by stabilizing HIF-1α via several mechanisms. Nonetheless, several undiscovered lncRNAs remain that may mediate or regulate the hypoxia axis. Consequently, the novel lncRNAs modulated by hypoxia or that influence hypoxia signaling have yet to be discovered and thoroughly described. Herein, we aim to classify suitable lncRNA targets to offer a feasible therapeutic modality for hypoxia-driven cancers.
Indexed as
Identifiers
40601072What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.